Disease · MONDO_0020563

dedifferentiated liposarcoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. dedifferentiated liposarcoma. Diseases, record MONDO_0020563. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0020563

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: dedifferentiated liposarcoma; Open Targets
Open Targets ID: MONDO_0020563; Open Targets
Other names: DDLPS, DDLS; Open Targets
Disease Ontology: DOID:0080531; Disease Ontology
NCI Thesaurus: C3704; NCI Thesaurus
Orphanet: ORPHA:99970; Orphanet
Highest stage of its drugs: Phase 3, for 6 of its 37 drugs, from ClinicalTrials.gov; Open Targets

Drugs37

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
BRIGIMADLIN	CHEMBL5314455	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
IFOSFAMIDE	CHEMBL1024	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
DACARBAZINE	CHEMBL476	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
MILADEMETAN	CHEMBL4292264	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SELINEXOR	CHEMBL3545185	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
DOXORUBICIN HYDROCHLORIDE	CHEMBL359744	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
RIBOCICLIB	CHEMBL3545110	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
ABEMACICLIB	CHEMBL3301610	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 37

See all 37 drugs

Targets73

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	8	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
CDK4	Cyclin-dependent kinase 4	3	Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 4/cyclin D1 inhibitor	Phase 2	https://conductscience.org/library/genes/1019	Drugs and targets
CDK6	CDK6/cyclin D1	3	CDK6/cyclin D1 inhibitor; Cyclin-dependent kinase 6 inhibitor	Phase 2	https://conductscience.org/library/genes/1021	Drugs and targets
HSP90AA1	Heat shock protein HSP90	2	Heat shock protein HSP90 inhibitor	Phase 2	https://conductscience.org/library/genes/3320	Drugs and targets
HSP90AB1	Heat shock protein HSP90	2	Heat shock protein HSP90 inhibitor	Phase 2	https://conductscience.org/library/genes/3326	Drugs and targets
TOP2A	DNA topoisomerase 2-alpha	2	DNA topoisomerase II alpha inhibitor	Phase 3	https://conductscience.org/library/genes/7153	Drugs and targets
ADORA2A	Adenosine receptor A2a	1	Adenosine A2a receptor antagonist	Phase 2	https://conductscience.org/library/genes/135	Drugs and targets
ADORA2B	Adenosine receptor A2b	1	Adenosine A2b receptor antagonist	Phase 2	https://conductscience.org/library/genes/136	Drugs and targets
ADRM1	26S proteasome	1	26S proteasome inhibitor	Phase 1	https://conductscience.org/library/genes/11047	Drugs and targets
CCND1	CDK6/cyclin D1	1	CDK6/cyclin D1 inhibitor; Cyclin-dependent kinase 4/cyclin D1 inhibitor	Phase 2	https://conductscience.org/library/genes/595	Drugs and targets

1 to 10 of 73

See all 73 targets

Trials34

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT05218499	Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma	Phase 2/3	400	2025-07-04	Liposarcoma, Dedifferentiated	BRIGIMADLIN, DOXORUBICIN	Its record names the disease	ClinicalTrials.gov
NCT02606461	Selinexor in Advanced Liposarcoma	Phase 2/3	342	2021-12-07	Dedifferentiated Liposarcoma	SELINEXOR	Its record names the disease	ClinicalTrials.gov
NCT04979442	Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma	Phase 3	175	2025-01-14	Dedifferentiated Liposarcoma	MILADEMETAN	Its record names the disease	ClinicalTrials.gov
NCT02301039	SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas	Phase 2	144	2020-09-29	Soft Tissue Sarcoma, Bone Sarcoma	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01209598	PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma	Phase 2	90	2017-11-06	Sarcoma, Liposarcoma	PALBOCICLIB	Its record names the disease	ClinicalTrials.gov
NCT02888665	Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery	Phase 1/2	37	2021-05-26	Sarcoma	DOXORUBICIN HYDROCHLORIDE, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01876043	Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial	Phase 2	24	2019-11-12	Adult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated Liposarcoma	PLITIDEPSIN	Its record names the disease	ClinicalTrials.gov
NCT05116683	ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma	Phase 2	4	2023-12-06	Leiomyosarcoma, Liposarcoma	DEOXYCHOLIC ACID, SODIUM DEOXYCHOLATE	Its record names the disease	ClinicalTrials.gov
NCT06422806	Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas	Phase 3	365		Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Unresectable Dedifferentiated Liposarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma	DOXORUBICIN, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03449381	This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)	Phase 1	266		Neoplasms	BRIGIMADLIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 34

See all 34 trials

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Milademetan vs Trabectedin: deaths from any cause	43 of 86	30 of 89	175	NCT04979442	Trial comparisons
Milademetan vs Trabectedin: Number of Participants With Treatment-emergent Adverse Events Until Approximately 30 Days After the Last Study Drug	86 of 86	78 of 79	165	NCT04979442	Trial comparisons
Milademetan vs Trabectedin: serious adverse events	31 of 86	38 of 79	165	NCT04979442	Trial comparisons
Palbociclib 200mg vs Palbociclib 125mg: serious adverse events	24 of 30	55 of 60	90	NCT01209598	Trial comparisons
Phase 1 Cohort 1 vs Phase 1 Cohort 2: Maximum Tolerated Dose (MTD) of Doxorubicin Hydrochloride Plus Pembrolizumab According to the National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) Version 4.0 (Phase I)	0 of 3	0 of 3	6	NCT02888665	Trial comparisons

Papers from its trials18

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
26041763	RESULT	1	PubMed
39547252	DERIVED	1	PubMed
39259562	DERIVED	1	PubMed
39034053	DERIVED	1	PubMed
38086314	DERIVED	1	PubMed
37269344	DERIVED	1	PubMed
36987836	DERIVED	1	PubMed
35394800	DERIVED	1	PubMed
32910151	DERIVED	1	PubMed
32827353	DERIVED	1	PubMed

1 to 10 of 18

See all 18 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0020563

GET https://conductscience.org/api/diseases/v1/MONDO_0020563/drugs?page=2

API reference For AI assistants